HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

AVE1625

structure in first source

Networked: 3 relevant articles (2 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133

Experts

1.	Arad, Michal: 1 article (05/2011)
2.	Barak, Segev: 1 article (05/2011)
3.	Black, Mark D: 1 article (05/2011)
4.	Borowsky, Beth: 1 article (05/2011)
5.	Cohen, Caroline: 1 article (05/2011)
6.	De Levie, Amaya: 1 article (05/2011)
7.	Featherstone, Robert E: 1 article (05/2011)
8.	Giardino, Odessa: 1 article (05/2011)
9.	Griebel, Guy: 1 article (05/2011)
10.	Pichat, Philippe: 1 article (05/2011)

Related Diseases

1.	Schizophrenia (Dementia Praecox) 05/01/2011 - "These studies investigated the effects of the CB1 receptor antagonist, AVE1625, in acute pharmacological and neurodevelopmental models of schizophrenia. " 05/01/2011 - "These preclinical data suggest that AVE1625 may be useful to treat the cognitive deficits in schizophrenia and as a co-treatment with currently available antipsychotics. " 05/01/2011 - "AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents."
2.	Cognitive Dysfunction 03/01/2010 - "CB1 antagonists such as AVE1625 are potentially useful in the treatment of obesity, smoking cessation and cognitive impairment. "
3.	Obesity 03/01/2010 - "CB1 antagonists such as AVE1625 are potentially useful in the treatment of obesity, smoking cessation and cognitive impairment. "
4.	Weight Gain 10/01/2010 - "Profiling of energy metabolism in olanzapine-induced weight gain in rats and its prevention by the CB1-antagonist AVE1625."
5.	Body Weight (Weight, Body) 10/01/2010 - "Combination of OLZ treatment with the CB1-antagonist AVE1625 attenuated body weight gain in rats." 10/01/2010 - "Coadministration of OLZ and AVE1625 (10 mg/kg orally once daily) attenuated body weight gain, diminishing the enhanced food intake while maintaining increased energy expenditure and decreased motility. " 10/01/2010 - "We further analyzed whether, and by which mechanism, the CB1-antagonist AVE1625 might attenuate OLZ-induced body weight gain. "

Related Drugs and Biologics

1.	CB1 Cannabinoid Receptor (CB1 Receptor)
2.	Antipsychotic Agents (Antipsychotics)
3.	Cannabinoids
4.	Olanzapine (Zyprexa)